|
|
 |
|
Viewing report
|
|
|
|
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
Decision Resources, Inc., Oct 2009, Pages: 32
Biomarkers and imaging tools are enabling technologies in today’s clinical research efforts for neurological diseases. Whether to improve upon existing methods for monitoring disease progression or to discover validated measures to detect diseases earlier than before, nearly every neurology trial is relying on biomarkers and/or has an imaging component. Although some biomarkers and imaging tools are better than others, companies in this market that are aiming to unveil a truly unique or even a significantly improved therapy must incorporate biomarkers in their R&D strategies—it would be foolish not to.
Get the Answers You Need to Shape Your Strategy
The uses of biomarkers in neurology are varied—drug discovery, monitoring disease progression/drug action, and diagnostic development—and can depend on the indication.
- In what ways are biomarkers being explored in Parkinson’s disease compared with Alzheimer’s disease?
- How has the use of biomarkers aligned with an outcome measure for a study in ALS?
Clearly defined biomarkers in the neurology therapeutic area are missing.
- Are we close to discovering appropriate biomarkers for use in diagnostic tests to detect diseases early enough to truly change the therapeutic landscape in neurology?
Imaging modalities are used frequently in neurological drug and diagnostic research.
- How many industry-sponsored active studies are employing imaging tools as their biomarker intervention?
- Which indication(s) relies on imaging the most?
Scope
- High-interest neurological diseases: Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), multiple sclerosis (MS), and Parkinson’s disease (PD).
- Analysis of 117 biomarker-based clinical trials as of September 2009: Study type, phase in development, indication.
- A look at 75 biomarker/diagnostics-based deals across six years: Company type (large-cap, midcap, small-cap), deal type, and indication-specific.
Customers who bought this item also bought
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
The Central Nervous Systems Market 2010 Report
Biomarker and Diagnostic Opportunities Associated with Targeted Cancer Therapies
The Neurotechnology Industry 2011 Report
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H1, 2012
Neurodegenerative Drugs - Global Strategic Business Report
The Neurology Pipeline: A Strategic Review
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, Q1, 2011
Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth
|
|
|
|
